Afuco™ Anti-NOTCH2 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H67) (CAT#: AFC-TAB-H67)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human antibody to Human NOTCH2. It is a novel anti-cancer stem cell antibody identified by screening against the Notch3 receptor that binds to and prevents signaling through both the Notch2 and Notch3 receptors.

Specific Inquiry
  • Size:

  • Conjugation:

  • Endotoxin:

  • Purity:

  • Formats:

  • Isotype Switching:

  • Fc Engineering:

  • Modalities:

Custom Production

We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.

Sequences:
Isotype :
Purity :
Endotoxin :
Quantity :
Conjugation :
Fc Engineering :
Modalities :
Other Requirements:
We require custom production
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Subcellular Location
Normal Tissue
RNA Expression

Specifications

  • Host Species
  • Human
  • Derivation
  • human
  • Type
  • ADCC enhanced antibody
  • Specificity
  • NOTCH2 (notch 2) [Homo sapiens];
  • Species Reactivity
  • Human
  • Applications
  • IF, IP, Neut, FuncS, ELISA, FC
  • Conjugate
  • Unconjugated
  • Generic Name
  • Tarextumab
  • Related Disease
  • Pancreatic cancers

Product Property

  • Purity
  • >95% by SDS-PAGE
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • NOTCH2; notch 2; Notch (Drosophila) homolog 2, Notch homolog 2 (Drosophila); neurogenic locus notch homolog protein 2; Notch homolog 2; hN2; AGS2; HJCYS;

Related Resources

  • Biosimilar Overview
  • Related Diseases
Please refer to Tarextumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Tarextumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Tarextumab"

DrugMonitor™ Anti-Tarextumab Antibody (VS-1224-YC1158)
Tarextumab is a fully human monoclonal antibody targeting Notch 2/3 receptors, studied in trials for solid tumors, Stage IV pancreatic cancer, and Stage IV small cell lung cancer. The DrugMonitor™ Anti-Tarextumab Antibody (VS-1224-YC1158) is an anti-drug antibody (ADA) against Tarextumab. This drug-based antibody is raised in mice immunized with the Tarextumab. The anti-Tarextumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Tarextumab in samples.

See other products for "NOTCH2"

Select a product category from the dropdown menu below to view related products.
Please select product type
Human Antibody Products IgG Antibody Products ScFv Antibody Products Fab Antibody Products Antibody Magnetic Beads Cancer Stem Cell Biomarker Specific Antibody Products Flow Cytometry (FC) related Reagents and Kits: Empowering Cell Function Research ScFv-Fc Chimera Products IHC Kit and Antibody Products: Precision Tools for Immunohistochemistry Extracellular Vesicle (EV) Antibody Products

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for AFC-TAB-H67. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to compare

Go to compare